John A. Stalfort III

CIK: 0001709418

Transaction Breakdown

Open Market Buys (P)1 (16.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)1 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ABOS

Acumen Pharmaceuticals, Inc.

Director

TSHA

Taysha Gene Therapies, Inc.

Director

VRCA

Verrica Pharmaceuticals Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ABOS
Acumen Pharmaceuticals, Inc.
Jun 3, 2026
Award(A)
Direct
35.5K shares-
TSHA
Taysha Gene Therapies, Inc.
Jun 1, 2026
Award(A)
Direct
21.3K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 4, 2025
Award(A)
Direct
12.8K shares-
TSHA
Taysha Gene Therapies, Inc.
Jun 2, 2025
Award(A)
Direct
56.6K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 26, 2024
Gift(G)
Direct
50K shares-
VRCA
Verrica Pharmaceuticals Inc.
Nov 22, 2024
Purchase(P)
Direct
1.1M shares-

		Type	Shares	Price		Ownership
Jun 3, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	35,500	-	$0	Direct
Jun 1, 2026	TSHA Taysha Gene Therapies, Inc.	Award(A)	21,335	-	$0	Direct
Jun 4, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	12,800	-	-	Direct
Jun 2, 2025	TSHA Taysha Gene Therapies, Inc.	Award(A)	56,623	-	-	Direct
Nov 26, 2024	VRCA Verrica Pharmaceuticals Inc.	Gift(G)	50,000	-	$0	Direct
Nov 22, 2024	VRCA Verrica Pharmaceuticals Inc.	Purchase(P)	1,123,595	-	$0	Direct

1-6 of 6 transactions

About Stalfort John A III

Stalfort John A III (SEC CIK 0001709418) files insider reports with the SEC as Director of Acumen Pharmaceuticals, Inc. (ABOS), Director of Taysha Gene Therapies, Inc. (TSHA) and Director of Verrica Pharmaceuticals Inc. (VRCA).

Signal8 holds 5 ownership filings by Stalfort John A III, all Form 4s, filed between Nov 26, 2024 and Jun 5, 2026. Those filings report 6 transactions, from Nov 22, 2024 to Jun 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Stalfort John A III's filings is in DALLAS, TX.

Recent filings by Stalfort John A III

Jun 3, 2026: Grant or award of ABOS shares (Form 4, code A).
Jun 1, 2026: Grant or award of TSHA shares (Form 4, code A).
Jun 4, 2025: Grant or award of ABOS shares (Form 4, code A).
Jun 2, 2025: Grant or award of TSHA shares (Form 4, code A).
Nov 26, 2024: Gift of VRCA shares (Form 4, code G).

Other insiders filing for Acumen Pharmaceuticals, Inc. (ABOS)

How to read Form 4 transaction codes